What is already known about this subject
• The effectiveness and safety of rivaroxaban in stroke prevention of AF
patients varied among studies (RCTs and observational studies).
• Difference in patient characteristics could be a common barrier
leading to the outcome discrepancies across studies. Besides, difference
in data source, outcome measures, and patient adherence, as well as
confounding bias of observational studies, all contribute to the
discrepant results.